Early colchicine before drug-eluting stent placement for non‑STEMI patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Inflammation plays a central role in atherosclerosis and may affect outcomes after PCI, and colchicine is an anti‑inflammatory drug with supportive data in chronic coronary disease. This early-phase interventional trial gives a colchicine loading dose before PCI and continues short-term colchicine versus placebo in patients with non‑STEMI receiving drug‑eluting stents. Short-term clinical endpoints and inflammation-related biomarkers will be compared between the colchicine and placebo groups to gauge peri-procedural effects. The trial is conducted at Assiut University Hospitals and focuses on immediate post-PCI outcomes rather than long-term event reduction.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with Non-STEMI
* Undergoing PCI with drug-eluting stents

Exclusion Criteria:

* Severe renal or hepatic dysfunction
* Colchicine hypersensitivity
* Active infection and active diarrhea.
* Gastrointestinal intolerance
* Pregnancy or breastfeeding.
* Cardiogenic shock

Where it's running

• Assiut University Hospitals
  Asyut, Asyut Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Resident Doctor
• Email: david.17289616@med.aun.edu.eg
• Phone: +201272615212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using low-dose colchicine to treat acute coronary syndromes

  This study tests if adding low-dose colchicine to standard treatment can help people with acute coronary syndromes avoid serious heart problems.

  Recruiting Beijing Anzhen Hospital · Beijing, Beijing Municipality · NCT06215989

• Antithrombotic options for acute coronary syndrome with coronary artery ectasia

  This trial tests whether using rivaroxaban instead of the usual aspirin plus clopidogrel better prevents clot-related complications in adults hospitalized with acute coronary syndrome who have coronary artery ectasia.

  Recruiting Phase 4 Instituto Nacional de Cardiologia Ignacio Chavez · Mexico City, Tlalpan · NCT07511257

• Crystalline sirolimus-coated balloon for treating coronary artery disease

  This tests whether a crystalline sirolimus-coated balloon is safe and effective for adults having percutaneous coronary intervention for coronary artery blockages or in-stent restenosis.

  Recruiting Fundación Interhospitalaria para la Investigación Cardiovascular FIC · Vigo, Pontevedra · NCT07444957

• Aspirin alone versus aspirin plus fondaparinux before early coronary angiography for NSTEMI

  This trial will test whether giving aspirin alone or aspirin plus the anticoagulant fondaparinux before early coronary angiography is better and safer for adults with NSTEMI.

  Recruiting at 7 sites Phase 4 University of Aarhus · Herning, Region Midt and 9 other locations · NCT06710184

• Non-stenting approach for acute heart attack with non-severe narrowing

  A large, multicenter trial will test whether standard medical therapy alone works as well as using drug-eluting stents in patients with a recent heart attack and a culprit artery with mild to moderate narrowing.

  Recruiting Harbin Medical University · Harbin, Heilongjiang and 47 other locations · NCT07567625

• Abbreviated antithrombotic therapy after PCI in AF and MI

  This trial tests whether DOAC-only therapy works as well as DOAC plus clopidogrel after PCI in people with atrial fibrillation and a recent heart attack.

  Recruiting Chonnam National University Hospital · Gwangju, Gwangju · NCT07583784

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.